Table 2.
Patients and tumor characteristics at metastasis diagnosis in the whole population
| Non-IBC |
IBC |
All |
P value | |
|---|---|---|---|---|
| n = 6883 | n = 582 | N = 7465 | ||
| Age at metastasis diagnosis (years) | ||||
| Median (min; max) | 60.0 (22; 97) | 56.0 (22; 91) | 60.0 (22; 97) | <0.001 |
| Menopausal status at metastasis diagnosis,an (%) | ||||
| No | 2004 (29.1) | 218 (37.5) | 2222 (29.8) | <0.001 |
| Yes | 4812 (69.9) | 361 (62.0) | 5173 (69.3) | |
| NA (men) | 67 (1.0) | 3 (0.5) | 70 (0.9) | |
| Metastatic status at diagnosis, n (%) | ||||
| M0 | 4978 (72.3) | 272 (46.7) | 5250 (70.3) | <0.001 |
| De novo (M1) | 1905 (27.7) | 310 (53.3) | 2215 (29.7) | |
| Metastatic sites, n (%) | ||||
| Visceral disease | 4018 (58.4) | 326 (56.0) | 4344 (58.2) | 0.3 |
| Bone | 4001 (58.1) | 273 (46.9) | 4274 (57.3) | <0.001 |
| Brain | 499 (7.3) | 65 (11.2) | 564 (7.6) | <0.001 |
| Lung | 1754 (25.5) | 103 (17.7) | 1857 (24.9) | <0.001 |
| Lymph node | 1843 (26.8) | 207 (35.6) | 2050 (27.5) | <0.001 |
| Pleura | 739 (10.7) | 55 (9.5) | 794 (10.6) | 0.3 |
| Skin | 677 (9.8) | 95 (16.3) | 772 (10.3) | <0.001 |
| Liver | 1898 (27.6) | 159 (27.3) | 2057 (27.6) | 0.9 |
| Visceral involvement for M0, n (%) | ||||
| n | 4978 | 272 | 5250 | |
| Brain visceral metastasis | 440 (8.8) | 54 (19.9) | 494 (9.4) | <0.001 |
| Non-brain visceral metastasis | 2574 (51.7) | 101 (37.1) | 2675 (51.0) | |
| Non-visceral metastasis | 1964 (39.5) | 117 (43.0) | 2081 (39.6) | |
| Visceral involvement for M1, n (%) | ||||
| n | 1905 | 310 | 2215 | |
| Brain visceral metastasis | 59 (3.1) | 11 (3.5) | 70 (3.2) | 0.7 |
| Non-brain visceral metastasis | 945 (49.6) | 160 (51.6) | 1105 (49.9) | |
| Non-visceral metastasis | 901 (47.3%) | 139 (44.8%) | 1040 (47.0) | |
| Number of metastatic sites | ||||
| Median (min; max) | 1.0 (1; 8) | 1.0 (1; 6) | 1.0 (1; 8) | 0.4 |
| Delay between initial diagnosis and metastases onset (year) only for M0 | ||||
| n | 4978 | 272 | 5250 | |
| Median (min; max) | 4.90 (0.50; 47.94) | 2.02 (0.50; 31.41) | 4.68 (0.50; 47.94) | <0.001 |
| Diagnosis of metastatic relapse, n (%) | ||||
| Systematic examination | 3446 (52.9) | 356 (63.3) | 3802 (53.7) | <0.001 |
| Symptom | 3072 (47.1) | 206 (36.7) | 3278 (46.3) | |
| Missing data | 365 | 20 | 385 | |
| Local or locoregional relapse, n (%) | ||||
| None | 6183 (89.9) | 537 (92.3) | 6720 (90.1) | 0.1 |
| Local relapse | 176 (2.6) | 8 (1.4) | 184 (2.5) | |
| Locoregional relapse | 516 (7.5) | 37 (6.4) | 553 (7.4) | |
| Missing data | 8 | 0 | 8 | |
| First-line treatment, n (%) | ||||
| Chemotherapy ± endocrine therapy ± target therapy | 4413 (66.8) | 477 (86.4) | 4890 (68.3) | <0.001 |
| Endocrine therapy ± target therapy | 2198 (33.2) | 75 (13.6) | 2273 (31.7) | |
IBC, inflammatory breast cancer; M0, no metastasis at diagnosis and until 6 months after diagnosis; M1, de novo metastatic disease; NA, not applicable.
a
Menopausal status determined by sex and age (cut-off of 52 years).